In recent years, in addition to a decrease in birth rate, the number of mothers ā„ 35 has been increasing (
1). Based on this fact, and also the high incidence of Down syndrome with maternal age, as well as some other chromosomal anomalies, the efforts for prenatal diagnosis of these disorders have risen (
2). In spite of introducing non-invasive prenatal tests, including prenatal aneuploidy screening program combined with NT (nuchal translucency), invasive antenatal test is yet widely being used around the world (
3)). Amniocentesis is the gold standard and most commonly an invasive antenatal test for diagnosis of fetal chromosome abnormalities (
4). Most of these abnormalities are numerical, and minority are structural and mosaicism (about 86%, 6%, and 8%, respectively) (
5,
6). Various clinical indications affect the distribution of prenatal chromosome abnormality identification 4. Introduction of non-invasive prenatal testing changed the frequency of chromosomal abnormalities. However, cell-free fetal DNA testing, as the best screening test for common chromosomal abnormalities, failed to be a universal prenatal aneuploidy screening due to its high cost and false positive rate (
7). Trisomy 21, known as Down syndrome, is the most prevalent chromosomal abnormality, which is associated with intellectual disability. The rates of fetal chromosomal aneuploidies in central Iran, Tehran, and north of Iran is 5.2%, 3.1%, and 1.5% - 1.7%, respectively (
6).